A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Breast cancer remodels lymphatics in sentinel lymph nodes
Tekijät: Eichin, Dominik; Lehotina, Diana; Kauko, Anni; Uenaka, Maki; Leppänen, Meri; Elima, Kati; Piipponen, Minna; Lönnberg, Tapio; Boström, Pia; Koskivuo, Ilkka; Aittokallio, Tero; Hollmén, Maija; Takeda, Akira; Jalkanen, Sirpa
Kustantaja: Springer Science and Business Media LLC
Julkaisuvuosi: 2025
Artikkelin numero: 10056
Vuosikerta: 16
Numero: 1
ISSN: 2041-1723
eISSN: 2041-1723
DOI: https://doi.org/10.1038/s41467-025-64981-z
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.1038/s41467-025-64981-z
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/505444130
Cancer metastasis to sentinel lymph nodes (LNs) is often the first marker of potential disease progression. Although it is recognized that tumor-induced lymphangiogenesis facilitates metastasis into LNs in murine models, tumor-induced alterations in human lymphatic vessels remain obscure. Here we use single-cell RNA sequencing and high-resolution spatial transcriptomics to profile lymphatic endothelial cell (LEC) subsets in paired metastatic and non-metastatic LNs obtained from female patients with treatment-naïve breast cancer. Tumor metastasis decreases immunoregulatory LEC subsets, such as PD-L1+ subcapsular sinus LECs, while inducing an increase in capillary-like CD200+ HEY1+ LECs. Matrix Gla protein (MGP) is the most upregulated gene in metastatic LN LECs, and its expression on LECs is TGF-β and VEGF dependent. Upregulated MGP promotes cancer cell adhesion to LN lymphatics. Thus, breast cancer cell metastasis to LNs remodels LEC subsets in human LNs and escalates MGP expression, potentially facilitating cancer cell dissemination through the lymphatic system.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This work was financed by the Research Council of Finland (A.T., M.H. and S.J.), the Finnish Cancer Foundation (M.H. and S.J.), Sigrid Juselius Foundation (A.T., M.H. and S.J.), Jane and Aatos Erkko Foundation (S.J.) and Sakari Alhopuro Foundation (A.T. and D.E.). The Turku Bioscience Centre Single-cell Omics Core Facility, the Finnish Functional Genomics Centre and Biocenter Finland are acknowledged for infrastructure support.
